Calreticulin Exon 9 Mutations in Myeloproliferative Neoplasms
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: Calreticulin (CALR) mutations were recently discovered in patients with myeloproliferative neoplasms (MPNs). We studied the frequency and type of CALR mutations and their hematological characteristics. Methods: A total of 168 MPN patients (36 polycythemia vera [PV], 114 essential thrombocythemia [ET], and 18 primary myelofibrosis [PMF] cases) were included in the study. CALR mutation was analyzed by the direct sequencing method. Results: CALR mutations were detected in 21.9% of ET and 16.7% of PMF patients, which accounted for 58.5% and 33.3% of ET and PMF patients without Janus kinase 2 (JAK2) or myeloproliferative leukemia virus oncogenes (MPL) mutations, respectively. A total of five types of mutation were detected, among which, L367fs*46 (53.6%) and K385fs*47 (35.7%) were found to be the most common. ET patients with CALR mutation had lower leukocyte counts and ages compared with JAK2-mutated ET patients. Conclusion: Genotyping for CALR could be a useful diagnostic tool for JAK2-or MPL-negative ET or PMF patients. CALR mutation may be a distinct disease group, with different hematological characteristics than that of JAK2-positive patients.
Abstract
Background: Calreticulin (CALR) mutations were recently discovered in patients with myeloproliferative neoplasms (MPNs). We studied the frequency and type of CALR mutations and their hematological characteristics. Methods: A total of 168 MPN patients (36 polycythemia vera [PV], 114 essential thrombocythemia [ET], and 18 primary myelofibrosis [PMF] cases) were included in the study. CALR mutation was analyzed by the direct sequencing method. Results: CALR mutations were detected in 21.9% of ET and 16.7% of PMF patients, which accounted for 58.5% and 33.3% of ET and PMF patients without Janus kinase 2 (JAK2) or myeloproliferative leukemia virus oncogenes (MPL) mutations, respectively. A total of five types of mutation were detected, among which, L367fs*46 (53.6%) and K385fs*47 (35.7%) were found to be the most common. ET patients with CALR mutation had lower leukocyte counts and ages compared with JAK2-mutated ET patients. Conclusion: Genotyping for CALR could be a useful diagnostic tool for JAK2-or MPL-negative ET or PMF patients. CALR mutation may be a distinct disease group, with different hematological characteristics than that of JAK2-positive patients.
참고문헌 (14)
- Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders", N Engl J Med, 352, pp.1779~1790 (2005)
- Pikman Y, "MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia", PLoS Med, 3, pp.e270~ (2006)
- Tefferi A., "Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1", Leukemia, 24, pp.1128~1138 (2010)
- Klampfl T, "Somatic mutations of calreticulin in myeloproliferative neoplasms", N Engl J Med, 369, pp.2379~2390 (2013)
- Nangalia J, "Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2", N Engl J Med, 369, pp.2391~2405 (2013)
- Coppolino MG, "Calreticulin is essential for integrin-mediated calcium signalling and cell adhesion", Nature, 386, pp.843~847 (1997)
- Tefferi A, "CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons", Leukemia, 28, pp.1472~1477 (2014)
- Lundberg P, "Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms", Blood, 123, pp.2220~2228 (2014)
- Rotunno G, "Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia", Blood, 123, pp.1552~1555 (2014)
- Rumi E, "JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes", Blood, 123, pp.1544~1551 (2014)
- Li B, "Calreticulin mutations in Chinese with primary myelofibrosis", Haematologica (2014)
- Patnaik MM, "CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts", Leukemia, 28, pp.1370~1371 (2014)
- Vannucchi AM, "Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms : pathogenetic insight and diagnostic value", Leukemia, 28, pp.1811~1818 (2014)
- Tefferi A, "CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients", Leukemia, 28, pp.1494~1500 (2014)